A recent study of the smoking cessation drug Chantix has led a group of researchers to conclude that the drug should only be used as a last ditch effort to quit smoking.
According to the study users of Chantix are eight times more likely to commit suicide or suffer from depression when compared to other leading tobacco replacement products such as nicotine gum or the nicotine patch.
The new finding comes just one month after the Food and Drug Administration released two studies that stated use of the drug does not increase psychiatric problems such as depression. The FDA however said their studies were flawed because they were too small to identify rare events.
Speaking about their findings Dr Curt Furberg, professor of Public Health Sciences at Wake Forest Baptist Medical Center and co-author of the study published online in the Public Library of Science journal PLoS One said:
“Our study contradicts the implications of a recent review by the FDA showing no difference in psychiatric hospitalizations between varenicline and nicotine replacement patches.”
Dr. Furberg added:
“The FDA hospitalization studies were flawed because they could not capture most of the serious psychiatric side effects, including suicide, depression, aggression and assaults. These can be catastrophic events but do not normally result in hospitalization.”
The study is quick to point out that only 10 percent of Chantix users quit smoking within a one year period which makes taking the drug more dangerous then other successful options when psychological risk is added into the equation.
Have you successfully quit smoking thanks to Chantix?